

Emanuel Della-Torre

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6794175/emanuel-della-torre-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

94
papers

5,206
citations

35
h-index

71
g-index

109
ext. papers

6,774
ext. citations

4.9
avg, IF

5.79
L-index

#	Paper	IF	Citations
94	B-Lymphocytes in the Pathophysiology of Pancreatic Adenocarcinoma.. <i>Frontiers in Immunology</i> , 2022 , 13, 867902	8.4	0
93	Serum IgG4 elevation in hyper-inflamed COVID-19 patients. Author's reply. <i>European Journal of Internal Medicine</i> , 2021 ,	3.9	1
92	Treating Type 2 Autoimmune Pancreatitis With Colchicine: A Case Series. <i>Annals of Internal Medicine</i> , 2021 ,	8	1
91	IL-1 and IL-6 inhibition affects the neutralising activity of anti-SARS-CoV-2 antibodies in patients with COVID-19. <i>Lancet Rheumatology, The</i> , 2021 , 3, e829-e831	14.2	6
90	Emerging therapy options for IgG4-related disease. <i>Expert Review of Clinical Immunology</i> , 2021 , 17, 471-483	3.8	2
89	Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study. <i>Lancet Rheumatology, The</i> , 2021 , 3, e253-e261	14.2	75
88	Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation. <i>Frontiers in Immunology</i> , 2021 , 12, 675678	8.4	18
87	Outcomes of non-invasive ventilation as the ceiling of treatment in patients with COVID-19. <i>Panminerva Medica</i> , 2021 ,	2	5
86	Persistence of circulating T-follicular helper cells after rituximab is associated with relapse of IgG4-related disease. <i>Rheumatology</i> , 2021 , 60, 3947-3949	3.9	5
85	Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Respiratory Medicine, the</i> , 2021 , 9, 522-532	35.1	112
84	Correspondence on Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, e159	2.4	13
83	Treating life-threatening TAFRO syndrome with interleukin-1 inhibition. <i>European Journal of Internal Medicine</i> , 2021 , 87, 121-123	3.9	2
82	Efficacy and safety of rituximab for IgG4-related pancreato-biliary disease: A systematic review and meta-analysis. <i>Pancreatology</i> , 2021 , 21, 1395-1401	3.8	2
81	CD4 and CD8 cytotoxic T lymphocytes may induce mesenchymal cell apoptosis in IgG-related disease. <i>Journal of Allergy and Clinical Immunology</i> , 2021 , 147, 368-382	11.5	22
80	Urgent manifestations of immunoglobulin G-related disease. <i>Scandinavian Journal of Rheumatology</i> , 2021 , 50, 48-51	1.9	3
79	Nailfold capillaroscopy findings in patients with coronavirus disease 2019: Broadening the spectrum of COVID-19 microvascular involvement. <i>Microvascular Research</i> , 2021 , 133, 104071	3.7	21
78	Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors. <i>Clinical Microbiology and Infection</i> , 2021 , 27, 451-457	9.5	110

77	Efficacy and safety of rituximab biosimilar (CT-P10) in IgG4-related disease: an observational prospective open-label cohort study. <i>European Journal of Internal Medicine</i> , 2021 , 84, 63-67	3.9	6
76	The role of interleukin-17 in the pathogenesis of systemic sclerosis: Pro-fibrotic or anti-fibrotic?. <i>Journal of Scleroderma and Related Disorders</i> , 2021 , 6, 227-235	2.3	0
75	Utility of the "2019 ACR/EULAR classification criteria" for the management of patients with IgG4-related disease. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 761-765	5.3	1
74	Drug reaction with eosinophilia and systemic symptoms (DRESS) in patients with COVID-19. <i>Clinical Microbiology and Infection</i> , 2021 , 27, 1190-1192	9.5	3
73	Efficacy of a rational algorithm to assess allergy risk in patients receiving the BNT162b2 vaccine. <i>Vaccine</i> , 2021 , 39, 6464-6469	4.1	2
72	Serum IgG4 level predicts COVID-19 related mortality. <i>European Journal of Internal Medicine</i> , 2021 , 93, 107-109	3.9	4
71	Impact of the COVID-19 pandemic in patients with systemic lupus erythematosus throughout one year. <i>Clinical Immunology</i> , 2021 , 231, 108845	9	3
70	Mer tyrosine kinase as a possible link between resolution of inflammation and tissue fibrosis in IgG4-related disease. <i>Rheumatology</i> , 2021 , 60, 4929-4941	3.9	2
69	Mavrilimumab for severe COVID-19 - AuthorsReply. <i>Lancet Rheumatology, The</i> , 2020 , 2, e662-e663	14.2	3
68	Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. <i>Lancet Rheumatology, The</i> , 2020 , 2, e325-e331	14.2	612
67	Treating COVID-19 with colchicine in community healthcare setting. <i>Clinical Immunology</i> , 2020 , 217, 108490	9	53
66	Advances in the diagnosis and management of IgG4 related disease. <i>BMJ, The</i> , 2020 , 369, m1067	5.9	50
65	European Guideline on IgG4-related digestive disease - UEG and SGF evidence-based recommendations. <i>United European Gastroenterology Journal</i> , 2020 , 8, 637-666	5.3	39
64	GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. <i>Lancet Rheumatology, The</i> , 2020 , 2, e465-e473	14.2	130
63	Clinical phenotypes of IgG4-related disease reflect different prognostic outcomes. <i>Rheumatology</i> , 2020 , 59, 2435-2442	3.9	14
62	COVID-19 in systemic lupus erythematosus: Data from a survey on 417 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 1150-1157	5.3	29
61	Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1277-1285	2.4	164
60	Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic. <i>Frontiers in Pharmacology</i> , 2020 , 11, 598308	5.6	14

59	IgG4-related disease and allergen-specific immunotherapy. <i>Annals of Allergy, Asthma and Immunology</i> , 2020 , 124, 631-633	3.2	5
58	Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. <i>European Journal of Internal Medicine</i> , 2020 , 76, 43-49	3.9	270
57	Necrosis volume and Choi criteria predict the response to endoscopic ultrasonography-guided HybridTherm ablation of locally advanced pancreatic cancer. <i>Endoscopy International Open</i> , 2020 , 8, E151-E157	3.1	79
56	Colchicine as a new therapeutic option for antithyroid arthritis syndrome. <i>Rheumatology</i> , 2020 , 59, 1452-1453	3.4	4
55	Long-term efficacy of maintenance therapy with Rituximab for IgG4-related disease. <i>European Journal of Internal Medicine</i> , 2020 , 74, 92-98	3.9	26
54	The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 77-87	2.4	179
53	The 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4-Related Disease. <i>Arthritis and Rheumatology</i> , 2020 , 72, 7-19	9.5	113
52	Targeting IL-1, IL-6 or GM-CSF in COVID-19. Response to: More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia Rby Ferraccioli. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	8
51	Systemic lupus erythematosus and COVID-19: what we know so far. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	7
50	Impact of sarilumab on mechanical ventilation in patients with COVID-19. Response to: Correspondence on: Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation-an open-label cohort study Rby Della-Torre Rby Cheng and Zhang. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	5
49	Colchicine treatment in community healthcare setting to prevent severe COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	5
48	B lymphocytes contribute to stromal reaction in pancreatic ductal adenocarcinoma. <i>Oncolimmunology</i> , 2020 , 9, 1794359	7.2	8
47	B lymphocytes directly contribute to tissue fibrosis in patients with IgG-related disease. <i>Journal of Allergy and Clinical Immunology</i> , 2020 , 145, 968-981.e14	11.5	44
46	Dupilumab as a steroid-sparing treatment for IgG4-related disease. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	6
45	Lifetime Allergy Symptoms in IgG4-Related Disease: A Case-Control Study. <i>Arthritis Care and Research</i> , 2020 ,	4.7	2
44	Identification of galectin-3 as an autoantigen in patients with IgG-related disease. <i>Journal of Allergy and Clinical Immunology</i> , 2019 , 143, 736-745.e6	11.5	78
43	OP0167 B LYMPHOCYTES DIRECTLY CONTRIBUTE TO TISSUE FIBROSIS IN IGG4-RELATED DISEASE 2019 ,		1
42	Methotrexate as Induction of Remission Therapy for Type 1 Autoimmune Pancreatitis. <i>American Journal of Gastroenterology</i> , 2019 , 114, 831-833	0.7	9

41	Effects of glucocorticoids on B-cell subpopulations in patients with IgG4-related disease. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37 Suppl 118, 159-166	2.2	12
40	An International Multispecialty Validation Study of the IgG4-Related Disease Responder Index. <i>Arthritis Care and Research</i> , 2018 , 70, 1671-1678	4.7	62
39	A CD8 ⁺ Subset of CD4 ⁺ SLAMF7 ⁺ Cytotoxic T Cells Is Expanded in Patients With IgG4-Related Disease and Decreases Following Glucocorticoid Treatment. <i>Arthritis and Rheumatology</i> , 2018 , 70, 1133-1143	9.5	49
38	Intrathecal rituximab for IgG-related hypertrophic pachymeningitis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018 , 89, 441-444	5.5	25
37	IgG4-related disease: review of the histopathologic features, differential diagnosis, and therapeutic approach. <i>Apmis</i> , 2018 , 126, 459-476	3.4	59
36	Increase of circulating memory B cells after glucocorticoid-induced remission identifies patients at risk of IgG4-related disease relapse. <i>Arthritis Research and Therapy</i> , 2018 , 20, 222	5.7	25
35	Rituximab hypersensitivity in IgG4-related disease: successful desensitization in a patient with IgG4 rheumatoid factor. <i>International Journal of Rheumatic Diseases</i> , 2017 , 20, 276-279	2.3	8
34	Palate perforation differentiates cocaine-induced midline destructive lesions from granulomatosis with polyangiitis. <i>Acta Otorhinolaryngologica Italica</i> , 2017 , 37, 281-285	2.8	21
33	Quantitative measurement of 18F-FDG PET/CT uptake reflects the expansion of circulating plasmablasts in IgG4-related disease. <i>Rheumatology</i> , 2017 , 56, 2084-2092	3.9	45
32	Deconstructing IgG4-related disease involvement of midline structures: Comparison to common mimickers. <i>Modern Rheumatology</i> , 2017 , 27, 638-645	3.3	20
31	Roles of Plasmablasts and B Cells in IgG4-Related Disease: Implications for Therapy and Early Treatment Outcomes. <i>Current Topics in Microbiology and Immunology</i> , 2017 , 401, 85-92	3.3	20
30	IgG4-related disease in Italy: clinical features and outcomes of a large cohort of patients. <i>Scandinavian Journal of Rheumatology</i> , 2016 , 45, 135-45	1.9	70
29	Juxta-vertebral lesions in granulomatosis with polyangiitis. <i>Seminars in Arthritis and Rheumatism</i> , 2016 , 46, 356-360	5.3	10
28	IgG4-Related Disease 2016 , 311-320		2
27	Antineutrophil cytoplasmic antibody positivity in IgG4-related disease: A case report and review of the literature. <i>Medicine (United States)</i> , 2016 , 95, e4633	1.8	55
26	Clonal expansion of CD4(+) cytotoxic T lymphocytes in patients with IgG4-related disease. <i>Journal of Allergy and Clinical Immunology</i> , 2016 , 138, 825-838	11.5	197
25	Plasmablasts: A Promising Biomarker in IgG4-Related Disease 2016 , 65-72		
24	"How I manage" IgG4-Related Disease. <i>Journal of Clinical Immunology</i> , 2016 , 36, 754-763	5.7	31

23	Methotrexate for maintenance of remission in IgG4-related disease. <i>Rheumatology</i> , 2015 , 54, 1934-6	3.9	42
22	B-cell depletion attenuates serological biomarkers of fibrosis and myofibroblast activation in IgG4-related disease. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 2236-43	2.4	80
21	International Consensus Guidance Statement on the Management and Treatment of IgG4-Related Disease. <i>Arthritis and Rheumatology</i> , 2015 , 67, 1688-99	9.5	546
20	Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 190-5	2.4	314
19	Clinical Manifestations of IgG4-Related Disease in the Pharynx: Case Series and Review of the Literature. <i>Annals of Otolaryngology, Rhinology and Laryngology</i> , 2015 , 124, 173-8	2.1	21
18	Immunology of IgG4-related disease. <i>Clinical and Experimental Immunology</i> , 2015 , 181, 191-206	6.2	133
17	Are atopy and eosinophilic bronchial inflammation associated with relapsing forms of chronic rhinosinusitis with nasal polyps?. <i>Clinical and Molecular Allergy</i> , 2015 , 13, 23	3.7	12
16	Prevalence of atopy, eosinophilia, and IgE elevation in IgG4-related disease. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2014 , 69, 269-272	9.3	180
15	IgG4-related midline destructive lesion. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1434-6	2.4	35
14	De novo oligoclonal expansions of circulating plasmablasts in active and relapsing IgG4-related disease. <i>Journal of Allergy and Clinical Immunology</i> , 2014 , 134, 679-87	11.5	242
13	Circulating Th2 memory cells in IgG4-related disease are restricted to a defined subset of subjects with atopy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2014 , 69, 399-402	9.3	90
12	IgG4-related hypertrophic pachymeningitis: clinical features, diagnostic criteria, and treatment. <i>JAMA Neurology</i> , 2014 , 71, 785-93	17.2	146
11	IgG4-related disease and other causes of inflammatory meningeal disease. <i>Seminars in Neurology</i> , 2014 , 34, 395-404	3.2	8
10	Diagnostic value of IgG4 Indices in IgG4-related hypertrophic pachymeningitis. <i>Journal of Neuroimmunology</i> , 2014 , 266, 82-6	3.5	47
9	Optimal management of DRESS syndrome in course of infectious endocarditis. <i>Annals of Allergy, Asthma and Immunology</i> , 2013 , 110, 303-5	3.2	7
8	In vivo tests with "Tahini" sauce: new allergenic source to evaluate IgE-mediated hypersensitivity to sesame. <i>Annals of Allergy, Asthma and Immunology</i> , 2013 , 110, 209-10	3.2	13
7	Cerebrospinal fluid analysis in immunoglobulin G4-related hypertrophic pachymeningitis. <i>Journal of Rheumatology</i> , 2013 , 40, 1927-9	4.1	33
6	IgG4-related pachymeningitis: evidence of intrathecal IgG4 on cerebrospinal fluid analysis. <i>Annals of Internal Medicine</i> , 2012 , 156, 401-3	8	36

- 5 Atypical presentation of Churg-Strauss syndrome or an undescribed hypereosinophilic disease?. *Journal of Allergy and Clinical Immunology*, **2011**, 128, 908-11 11.5
- 4 Erdheim-Chester disease: imaging-guided therapeutic approach. *Clinical Nuclear Medicine*, **2011**, 36, 704-67 7
- 3 Causes of food-induced anaphylaxis in Italian adults: a multi-centre study. *International Archives of Allergy and Immunology*, **2009**, 150, 271-7 3.7 104
- 2 EpidemAAITO: features of food allergy in Italian adults attending allergy clinics: a multi-centre study. *Clinical and Experimental Allergy*, **2009**, 39, 547-55 4.1 93
- 1 Sildenafil in pulmonary hypertension. *Sarcoidosis Vasculitis and Diffuse Lung Diseases*, **2005**, 22, 78-9 1.1 5